My New York City practice has been a refractive-only practice for more than 25 years, offering the full range of FDA-approved vision correction surgery options, from lasers to IOLs.
The rate-limiting factors for presbyopia-correcting IOLs, in my opinion, have long been dysphotopsias and enhancements. When I first started implanting presbyopia-correcting IOLs, the side effect profile — primarily problems with night vision — was significant, and achieving good vision at all distances was challenging. Early on, I explanted about 4% to 5% of the multifocal IOLs I implanted and performed laser